Although FDA-approved vaccines are not presently available for advanced/metastatic NSCLC treatment, the benefits of PD1/PD-L1 inhibitors demonstrated in NSCLC patients serve as proof of principle that harnessing the immune system can lead to an anti-tumor effect. The gene discussed is CD274; the disease is non-small cell lung carcinoma.